GYRE THERAPEUTICS, INC. Operating Income Loss

• GYRE THERAPEUTICS, INC. showed a decrease of -28.9% in Operating Income Loss from 2024 to 2025.
• This data is from GYRE THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
• XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 17 years of available data (2009 to 2025), GYRE THERAPEUTICS, INC.'s Operating Income Loss has grown by 128.5%.
• Historical annual values: Fiscal year 2025: $11.49 million | Fiscal year 2024: $16.16 million | Fiscal year 2023: -$67.23 million | Fiscal year 2022: $9.20 million | Fiscal year 2021: -$87.89 million | Fiscal year 2020: -$57.37 million | Fiscal year 2019: -$57.28 million | Fiscal year 2018: -$33.82 million | Fiscal year 2017: -$21.82 million | Fiscal year 2016: -$20.42 million | Fiscal year 2015: -$13.80 million | Fiscal year 2014: -$7.51 million | Fiscal year 2013: -$10.12 million | Fiscal year 2012: -$8.14 million | Fiscal year 2011: -$9.75 million | Fiscal year 2010: $13.12 million | Fiscal year 2009: -$40.33 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026